Siemens to reduce stake in Siemens Healthineers
The decision is a “natural next step in our journey to becoming a fully independent company,” Siemens Healthineers CEO Bernd Montag said.
Uncategorized
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin deficiency. The company’s stock is down 80% on all the news.
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal Read More »
FDA’s Bad Rap: Pazdur Steps Up as Agency Continues To Take on Water
Unpredictable communication and a lack of transparency are eroding the industry’s and the public’s trust. The FDA, experts agree, needs to take control of the narrative.
FDA’s Bad Rap: Pazdur Steps Up as Agency Continues To Take on Water Read More »
Historic government shutdown ends, leaving ACA subsidies in limbo
The House passed a stopgap funding bill and President Donald Trump signed it late Wednesday, reopening the government without a clear path forward on preserving enhanced subsidies for ACA plans — Democrats’ chief demand.
Historic government shutdown ends, leaving ACA subsidies in limbo Read More »
FDA Unwraps ‘Plausible Mechanism Pathway’ for Personalized Therapies
The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed.
FDA Unwraps ‘Plausible Mechanism Pathway’ for Personalized Therapies Read More »
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes expects to launch a global late-stage program early next year for narcolepsy type 2.
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data Read More »
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+
In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial for amyotrophic lateral sclerosis.
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+ Read More »
Zealand Freezes Mid-Stage Obesity Asset to Focus on More Differentiated Drugs
The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for clinical differentiation” in obesity.
Zealand Freezes Mid-Stage Obesity Asset to Focus on More Differentiated Drugs Read More »
Recently Launched Third Arc Turns to China for Cancer T Cell Engagers
The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to disclose priority indications.
Recently Launched Third Arc Turns to China for Cancer T Cell Engagers Read More »
¿Entrelazamiento cuántico universal?
En sus fundamentos físicos más profundos, el universo parece comportarse como una unidad, un único sistema cuántico en vez de muchos independientes. A partir de esta reflexión, unos físicos han llegado a la conclusión de que el hecho de que t …